To demonstrate the safety and effectiveness of the Shockwave Reducer for treatment of patients with refractory angina pectoris treated with maximally tolerated guideline-directed medical therapy who demonstrate objective evidence of reversible myocardial ischemia in the distribution of the left coronary artery and who are deemed unsuitable for revascularization.

The primary objective of this trial is to evaluate the potential of dalcetrapib to reduce the occurrence of fatal and non-fatal myocardial infarction in subjects with a documented recent ACS and the AA genotype at variant rs1967309 in the ADCY9 gene.

The primary objective of this trial is to evaluate the potential of dalcetrapib to reduce the occurrence of fatal and non-fatal myocardial infarction in subjects with a documented recent ACS and the AA genotype at variant rs1967309 in the ADCY9 gene.

The purpose of this clinical trial is to demonstrate the safety and effectiveness of primary left ventricular (LV) unloading and a 30-minute delay-to-reperfusion versus current standard of care in reducing infarct size and heart failure-related clinical events in patients presenting with anterior ST-elevation myocardial infarction (STEMI).

The purpose of this clinical trial is to demonstrate the safety and effectiveness of primary left ventricular (LV) unloading and a 30-minute delay-to-reperfusion versus current standard of care in reducing infarct size and heart failure-related clinical events in patients presenting with anterior ST-elevation myocardial infarction (STEMI).